The report outlines Daiichi Sankyo's strategy for becoming a ""Global Pharma Innovator with competitive advantage in oncology."" Key highlights include the progress of its 5-year business plan, the development of its ADC and AML franchises, and its commitment to ESG issues. The report also includes details on the company's operations in Japan, the U.S., Europe, and ASCA, as well as its CSR activities.
Issuing Company Daiichi Sankyo Co., Ltd.
Report Type Sustainability Report
Report Language EN
Report Filesize 5.7 MB
No. of Pages 62 pages
Reporting periodApril 1, 2017 - March 31, 2018
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB; UNSDGs
Materiality Assessmenttrue